FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103826912> ?p ?o ?g. }

• W2103826912 endingPage "765" @default.
• W2103826912 startingPage "761" @default.
• W2103826912 abstract "The aim of the present study was to investigate the efficacy and side-effects of preventive treatment with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) on concurrent chemoradiotherapy-induced grade IV neutropenia and to provide a rational basis for its clinical application. A total of 114 patients with concurrent chemoradiotherapy-induced grade IV neutropenia were enrolled. A randomized approach was used to divide the patients into an experimental group and a control group. The experimental group included three subgroups, namely a P-50 group, P-100 group and P + R group. The P-50 group had 42 cases, which were given a single 50-μg/kg subcutaneous injection of PEG-rhG-CSF. The P-100 group had 30 cases, which received a single 100-μg/kg subcutaneous injection of PEG-rhG-CSF. The P + R group comprised 22 cases, which were given a single 50-μg/kg subcutaneous injection of PEG-rhG-CSF and rhG-CSF 5 μg/kg/day; when the absolute neutrophil count (ANC) was ≥2.0×109/l, the administration of rhG-CSF was stopped. The control group (RC group) comprised 20 patients, who received rhG-CSF 5 μg/kg/day by subcutaneous injection until the ANC was ≥2.0×109/l. Changes in the neutrophil proliferation rate and ANC values over time, the neutropenic symptom remission time and incidence of adverse drug reactions were analyzed statistically in each group of patients. In the experimental group, the neutrophil proliferation rate and ANC values were significantly higher than those in the control group; the clinical effects began 12-24 h after treatment in the experimental group, and indicated that the treatment improved neutropenia in ~48 h after treatment. There was no significant difference in the neutrophil proliferation rate and ANC values between the P-50 and P+R groups. In the experimental group, the remission time of neutropenia-induced fever and muscle pain after administration was significantly shorter than that in the control group, with a statistically significant difference (P<0.05). The adverse drug reaction rates showed no significant difference between the experimental group and the control group. PEG-rhG-CSF had good efficacy and safety in the treatment of concurrent chemotherapy-induced grade IV neutropenia. For the treatment of concurrent chemotherapy-induced grade IV neutropenia, a single subcutaneous injection of 50 μg/kg PEG-rhG-CSF is the recommended dose. The effects begin at 12-24 h; if the ANC values are not significantly improved during this time, no supplementary administration of rhG-CSF is necessary." @default.
• W2103826912 created "2016-06-24" @default.
• W2103826912 creator A5017941291 @default.
• W2103826912 creator A5031315906 @default.
• W2103826912 creator A5043802137 @default.
• W2103826912 creator A5059811201 @default.
• W2103826912 creator A5073582242 @default.
• W2103826912 creator A5081137437 @default.
• W2103826912 creator A5090366405 @default.
• W2103826912 creator A5090984051 @default.
• W2103826912 date "2014-12-30" @default.
• W2103826912 modified "2023-10-16" @default.
• W2103826912 title "Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia" @default.
• W2103826912 cites W1970523181 @default.
• W2103826912 cites W2038445365 @default.
• W2103826912 cites W2043370767 @default.
• W2103826912 cites W2058875082 @default.
• W2103826912 cites W2115170812 @default.
• W2103826912 cites W2164788594 @default.
• W2103826912 cites W2170779256 @default.
• W2103826912 cites W2351468013 @default.
• W2103826912 cites W2410571739 @default.
• W2103826912 cites W2161875770 @default.
• W2103826912 doi "https://doi.org/10.3892/etm.2014.2160" @default.
• W2103826912 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4316958" @default.
• W2103826912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25667625" @default.
• W2103826912 hasPublicationYear "2014" @default.
• W2103826912 type Work @default.
• W2103826912 sameAs 2103826912 @default.
• W2103826912 citedByCount "8" @default.
• W2103826912 countsByYear W21038269122017 @default.
• W2103826912 countsByYear W21038269122018 @default.
• W2103826912 countsByYear W21038269122021 @default.
• W2103826912 countsByYear W21038269122022 @default.
• W2103826912 countsByYear W21038269122023 @default.
• W2103826912 crossrefType "journal-article" @default.
• W2103826912 hasAuthorship W2103826912A5017941291 @default.
• W2103826912 hasAuthorship W2103826912A5031315906 @default.
• W2103826912 hasAuthorship W2103826912A5043802137 @default.
• W2103826912 hasAuthorship W2103826912A5059811201 @default.
• W2103826912 hasAuthorship W2103826912A5073582242 @default.
• W2103826912 hasAuthorship W2103826912A5081137437 @default.
• W2103826912 hasAuthorship W2103826912A5090366405 @default.
• W2103826912 hasAuthorship W2103826912A5090984051 @default.
• W2103826912 hasBestOaLocation W21038269122 @default.
• W2103826912 hasConcept C126322002 @default.
• W2103826912 hasConcept C141071460 @default.
• W2103826912 hasConcept C197934379 @default.
• W2103826912 hasConcept C203014093 @default.
• W2103826912 hasConcept C2776390293 @default.
• W2103826912 hasConcept C2776694085 @default.
• W2103826912 hasConcept C2777063308 @default.
• W2103826912 hasConcept C2777767877 @default.
• W2103826912 hasConcept C71924100 @default.
• W2103826912 hasConcept C74133956 @default.
• W2103826912 hasConcept C90924648 @default.
• W2103826912 hasConceptScore W2103826912C126322002 @default.
• W2103826912 hasConceptScore W2103826912C141071460 @default.
• W2103826912 hasConceptScore W2103826912C197934379 @default.
• W2103826912 hasConceptScore W2103826912C203014093 @default.
• W2103826912 hasConceptScore W2103826912C2776390293 @default.
• W2103826912 hasConceptScore W2103826912C2776694085 @default.
• W2103826912 hasConceptScore W2103826912C2777063308 @default.
• W2103826912 hasConceptScore W2103826912C2777767877 @default.
• W2103826912 hasConceptScore W2103826912C71924100 @default.
• W2103826912 hasConceptScore W2103826912C74133956 @default.
• W2103826912 hasConceptScore W2103826912C90924648 @default.
• W2103826912 hasIssue "3" @default.
• W2103826912 hasLocation W21038269121 @default.
• W2103826912 hasLocation W21038269122 @default.
• W2103826912 hasLocation W21038269123 @default.
• W2103826912 hasLocation W21038269124 @default.
• W2103826912 hasOpenAccess W2103826912 @default.
• W2103826912 hasPrimaryLocation W21038269121 @default.
• W2103826912 hasRelatedWork W2058955695 @default.
• W2103826912 hasRelatedWork W2061928026 @default.
• W2103826912 hasRelatedWork W2114989931 @default.
• W2103826912 hasRelatedWork W2120457371 @default.
• W2103826912 hasRelatedWork W2338649218 @default.
• W2103826912 hasRelatedWork W2364106504 @default.
• W2103826912 hasRelatedWork W2382519218 @default.
• W2103826912 hasRelatedWork W2413360557 @default.
• W2103826912 hasRelatedWork W2417492975 @default.
• W2103826912 hasRelatedWork W4242705436 @default.
• W2103826912 hasVolume "9" @default.
• W2103826912 isParatext "false" @default.
• W2103826912 isRetracted "false" @default.
• W2103826912 magId "2103826912" @default.
• W2103826912 workType "article" @default.